SNDX
$23.77
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
Intraday
Recent News
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research.
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned
This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts
Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst. The analyst calls on uniQure (NASDAQ:QURE), Syndax Pharmaceuticals (NASDAQ:SNDX), and Erasca (NASDAQ:ERAS) share a common thread: analysts see asymmetric upside in names where the market has not yet priced in the full probability of success. uniQure: ... uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts
Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs
Syndax Pharmaceuticals (NASDAQ:SNDX) is one of the best cancer stocks to invest in now. On February 15, at the Guggenheim biotech conference, Chief Executive Officer Michael Metzger reiterated that Syndax Pharmaceuticals (NASDAQ:SNDX) started 2026 on a strong footing, going by the commercial performance of two key marketed products. In addition, the company is making significant […]
Is Syndax (SNDX) Using ESOP Shares and New Drugs to Quietly Redefine Its Investment Story?
Syndax Pharmaceuticals recently filed a US$77.73 million shelf registration for 3,746,239 common shares related to its employee stock ownership plan and reported Q4 2025 results showing strong revenue growth but a wider-than-expected loss. The combination of robust uptake of Revuforj and Niktimvo, three FDA approvals within a year, and a solid cash position highlights Syndax’s growing commercial scale and funding flexibility. We’ll now examine how Syndax’s accelerating product revenues and...